Immunovant, Inc.
IMVT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001764013
In the last 90 days, Immunovant, Inc. insiders filed 0 open-market purchases and 10 sales; 226 institutions reported holding it in 13F filings for Q2 2026, worth $4.25B in total; Greenlight Capital is the only superinvestor holding it.
Q3 2022 vs. Q2 2022
How the institutions holding Immunovant, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 94 | 112 | +18 |
| Shares | 40.1M | 42.7M | +2.53M (+6.3%) |
| Value | $156.5M | $238.1M | +$81.6M (+52.1%) |
New holders (23)
Institutions that held Immunovant, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
Sold out (5)
Institutions that held Immunovant, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| DuPont Capital Management Corp | 34,088 | $133.0K |
| Bridgefront Capital, LLC | 15,649 | $61.0K |
| Penserra Capital Management LLC | 3,597 | $14.0K |
| International Biotechnology Trust PLC | 233 | – |
| PEAK6 Investments LLC | 13,000 | – |